DURAMED ANSWERS NATIONAL CALL FOR TUBERCULOSIS DRUG
DURAMED ANSWERS NATIONAL CALL FOR TUBERCULOSIS DRUG CINCINNATI, March 30 /PRNewswire/ -- Duramed Pharmaceuticals, Inc.
will re-enter the tuberculosis medication market with Isoniazid, the generic equivalent of the brand drug INH, Duramed chairman and president E. Thomas Arington announced today.
Arington also announced that the company had received U.S. Food and Drug Administration (FDA) approval of its manufacturing process validation on March 26, 1992. In response to the urgent need for this critical medication, Duramed will begin shipping immediately. Recently, the number of tuberculosis cases in the United States has risen steadily, and worldwide it causes more deaths than any other infectious disease. Current estimates are that eight million people will develop active tuberculosis each year, and three million will die as a result. "The recent resurgence of tuberculosis has created an increased demand for affordable medication to treat the disease," Arington stated. "Our decision to resume manufacturing and marketing Isoniazid is in direct response to that need." Duramed Pharmaceuticals, Inc. manufactures and sells generic drug products composed of various dosages of prescription and over-the-counter drugs. -0- 3/30/92 /CONTACT: Bill Roberts or John Maginnis, public relations consultants, Cameron Towey Central, 513-891-1818, for Duramed Pharmaceuticals, Inc./ CO: Duramed Pharmaceuticals, Inc. ST: Ohio IN: MTC SU:
KK -- CL015 -- 2882 03/30/92 12:10 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 30, 1992|
|Previous Article:||GREAT LAKES BANCORP SHAREHOLDER REQUESTS SPECIAL MEETING|
|Next Article:||NATION'S TOP LAW FIRMS JOIN NATIONAL UNION PANEL COUNSEL TO REPRESENT D&O INSUREDS|